Display Settings:

Format

Send to:

Choose Destination

    Mol Cell Biol. 1997 Mar;17(3):1535-42.

    Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

    Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB.

    Department of Medicine, University of Chicago, Illinois 60637, USA.

    CD30 is a lymphoid cell-specific surface receptor which was originally identified as an antigen expressed on Hodgkin's lymphoma cells. Activation of CD30 induces the nuclear factor kappaB (NF-kappaB) transcription factor. In this study, we define the domains in CD30 which are required for NF-kappaB activation. Two separate elements of the cytoplasmic domain which were capable of inducing NF-kappaB independently of one another were identified. The first domain (domain 1) mapped to a approximately 120-amino-acid sequence in the membrane-proximal region of the CD30 cytoplasmic tail, between residues 410 and 531. A second, more carboxy-terminal region (domain 2) was identified between residues 553 and 595. Domain 2 contains two 5- to 10-amino-acid elements which can mediate the binding of CD30 to members of the tumor necrosis factor receptor-associated factor (TRAF) family of signal transducing proteins. Coexpression of CD30 with TRAF1 or TRAF2 but not TRAF3 augmented NF-kappaB activation through domain 2 but not domain 1. NF-kappaB induction through domain 2 was inhibited by coexpression of either full-length TRAF3 or dominant negative forms of TRAF1 or TRAF2. In contrast, NF-kappaB induction by domain 1 was not affected by alterations in TRAF protein levels. Together, these data support a model in which CD30 can induce NF-kappaB by both TRAF-dependent and -independent mechanisms. TRAF-dependent induction of NF-kappaB appears to be regulated by the relative levels of individual TRAF proteins in the cell.

    PMID: 9032281 [PubMed - indexed for MEDLINE]

    PMCID: PMC231879

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read